Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 47, 2017 - Issue 10
426
Views
21
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

An open-label, single-dose, phase 1 study of the absorption, metabolism and excretion of quizartinib, a highly selective and potent FLT3 tyrosine kinase inhibitor, in healthy male subjects, for the treatment of acute myeloid leukemia

, , , , &
Pages 856-869 | Received 06 Jun 2016, Accepted 21 Jul 2016, Published online: 25 Jul 2017
 

Abstract

1. Quizartinib absorption, metabolism and excretion were characterized in six healthy men receiving a single oral dose of 60 mg (≈100 μCi) of [14C]-quizartinib. Blood, plasma, urine and faeces were collected ≤336 h postdose.

2. Four hours postdose, maximum mean ± SD blood radioactivity concentrations were 296 ± 67.4 ng equivalents/g. A mean ± SD of 1.64 ± 0.482% and 76.3 ± 6.23% of the dose was recovered in urine and faeces, respectively, within 336 h postdose.

3. Radio-detector high-performance liquid chromatography (radio-HPLC) and liquid chromatography–mass spectrometry (LC–MS) showed two main radioactive peaks in plasma, unchanged quizartinib and mono-oxidative metabolite, AC886. Five additional metabolites in plasma were identified by LC–MS, but low levels prevented radio-HPLC detection. Although unchanged quizartinib was the main radioactive component in faeces (mean, 4.0% of administered dose), 15 metabolites representing a mean of 1.0–3.5% of administered dose were found. Quizartinib was predominantly metabolized by phase I biotransformations (oxidation, reduction, dealkylation, deamination, hydrolysis and combinations thereof).

4. This study indicated that quizartinib was rapidly and orally bioavailable, extensively metabolized, with AC886 as the major circulating metabolite, and predominantly eliminated in faeces. Quizartinib was well tolerated in the subjects.

Acknowledgements

We thank Nate Ensrud for directing the radioanalysis of the human samples, James Pombier for assistance with preparation of the manuscript, Ryan Berko for the conduct of metabolite profiling in human samples and Gayle Bresnahan for study conduct. Editorial assistance was provided by SciMentum, Inc., a Nucleus Global company, funded by Daiichi Sankyo, Inc.

Declaration of interest

The authors have no declarations or conflicts of interest.

This work was supported by funding from Daiichi Sankyo Company, New Jersey, USA.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 897.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.